Uncategorized

IBS Treatment Market Research Report till 2023: In-depth Qualitative and Quantitative Study

Press Release

IBS Treatment Market Information: By Types, (IBS-D, IBS-C, And IBS-M), By Drugs Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, And Others), By End Users (Hospitals, Clinics, And Research Laboratories) – Americas Forecast Till 2023

Market Analysis
Irritable bowel syndrome (IBS) is one of the major disorders affecting the digestive system of humans. Diarrhea, bloating, stomach cramps, and constipation, are some of the symptoms of the disorder. In spite of the fact that the reason for IBS is obscure, however, few factors that cause IBS are extreme disease, inflammation of the digestion tracts, contraction of muscles in the intestine, changes in gut bacteria, and nerve disorders. The rising pervasiveness of gastrointestinal infections and confusion, the geriatric populace, undesirable eating regimen, uneasiness, depression, and changing way of life in the Americas are the key drivers of the Americas IBS market. The Americas IBS treatment market is projected to grow at a CAGR of 9.3% during the forecast period 2017-2023.

Access this report @ https://www.reportocean.com/industry-verticals/sample-request?report_id=19251

Moreover, expanding consumer awareness about the IBS syndrome has increased the footfall of patient in the hospitals and other healthcare centers. Moreover, expanding expenditure in the medicinal services area is fueling the development of the IBS treatment market. However, strict FDA controls and inadmissible adequacy of the treatment may harm the development of the Americas IBS treatment market amid the forecast period (2017-2023).

Market Segmentation 
The Americas IBS treatment market is segmented on the basis of its drugs type, types, end user and regional analysis. Based on its drugs type, the Americas IBS treatment market is sectioned into linaclotide, lubiprostone, eluxadoline, alosetron, rifaximin, and others. On the basis its types, the market is classified into IBS-C, IBS-D, IBS-M. Based on its end users, it is divided into clinics, research laboratories, and hospitals.

Regional Analysis
Geographically, the Americas IBS treatment market is divided into global regions like

  • Europe
  • Asia Pacific (APAC)
  • North America
  • The Middle East and Africa (MEA)
  • Latin America

Major Players
The list of key players in Americas IBS treatment market include companies like Allergan Plc (Ireland), Ironwood Pharmaceuticals, Inc. (U.S.), Sucampo Pharmaceuticals (U.S.), Astellas Pharma Inc. (Japan), Abbott Laboratories (U.S.), Valeant Pharmaceuticals (Canada), Synergy Pharmaceuticals, Inc. (U.S.), Nestle (Switzerland), Ardelyx, Inc. (U.S.), Sebela Pharmaceuticals (Ireland), Alfasigma USA, Inc. (Italy), Probi (Sweden), RedHill Biopharma Ltd. (Israel), Ipsen (France), AstraZeneca (U.K), Novartis AG (Switzerland), Synthetic Biologics, Inc. (U.S.), Takeda Pharmaceutical Company Ltd (Japan), Protagonist Therapeutics Inc. (U.S.), Lexicon Pharmaceuticals, Inc. (U.S.), Pfizer Inc (U.S.), 4D pharma plc (U.K), Innovate Biopharmaceuticals (U.S.), among others.

Complete Report Details @ https://www.reportocean.com/industry-verticals/sample-request?report_id=19251

TABLE OF CONTENT     

1 Report Prologue
2 Market Introduction
2.1 Scope of Study
2.2 Research Objective
2.3 Assumptions & Limitations
2.3.1 Assumptions
2.3.2 Limitations
2.4 Market Structure
3 Research Methodology
3.1.1 Primary Research Methodology
3.1.2 Data points received from the doctors/ gastrologist:
3.1.3 Data points received from the manufacturer/ pharmaceutical companies:
3.1.4 Data points received from Hospitals, Clinics:
3.1.5 Secondary Research Methodology
3.1.6 Market Share Analysis
3.1.7 Trade Analysis
3.1.8 Market Pricing Approach
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Increasing prevalence of anxiety (Impact Weightage: 37%)
4.2.2 Strong clinical pipeline (Impact Weightage: 35%)
4.2.3 Increasing prevalence of depression (Impact Weightage: 28%)
4.3 Restraints
4.3.1 Strict FDA regulations (Impact Weightage: 60%)
4.3.2 Unsatisfactory effectiveness of the treatment (Impact Weightage: 40%)
4.4 Opportunity
4.5 Mega Trends
4.6 Macroeconomic Indicators

Continued…

Get more information, Ask for free sample copy of this @ https://www.reportocean.com/industry-verticals/sample-request?report_id=19251

Contact Us:
Company Name: Report Ocean
Address: Classic Tower, Rajnagar Extension, Ghaziabad, 201017 – India
Contact: +1 888 212 3539 (US) +91-9997112116 (Outside US)
Contact Name: Varda
URL: www.reportocean.com
email: [email protected]